Arrowhead Pharmaceuticals, Inc.
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|
| Revenue | $31.4M | $158.3K | $382.0K | $175.0K | $290.3K | $146.9K | $296.1K |
| Cost of Revenue | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — |
| Operating Expenses | |||||||
| Research & Development | — | — | $47.3M | $23.1M | $8.7M | $5.4M | $3.3M |
| SG&A Expense | $17.5M | $23.6M | $7.9M | $5.9M | $3.5M | $6.4M | $3.8M |
| Operating Income | $-37.0M | $-81.7M | $-96.0M | $-53.3M | $-24.6M | $-21.1M | $-9.8M |
| Operating Margin | -117.8% | -51,627.1% | -25,124.1% | -30,443.6% | -8,471.3% | -14,358.6% | -3,319.5% |
| Interest Expense | — | — | — | — | — | — | — |
| Pretax Income | $-34.4M | $-81.7M | $-91.9M | $-58.7M | $-31.7M | $-22.1M | $-8.8M |
| Income Tax Expense | $2.4K | $2.4K | $2.4K | $5.3K | — | — | — |
| Net Income | $-34.4M | $-81.7M | $-91.9M | $-58.6M | $-31.1M | $-21.1M | $-3.1M |
| Net Margin | -109.5% | -51,614.6% | -24,068.3% | -33,503.0% | -10,729.2% | -14,383.6% | -1,056.6% |
| EPS (Basic) | $-0.47 | $-1.34 | $-1.60 | $-1.25 | $-1.30 | $-1.90 | $-0.44 |
| EPS (Diluted) | $-0.47 | $-1.34 | $-1.60 | $-1.25 | $-1.30 | $-1.90 | $-0.40 |
| Shares Outstanding (Basic) | 73.9M | 74.2M | 59.6M | 54.7M | 38.7M | 11.1M | 7.2M |
| Shares Outstanding (Diluted) | 73.9M | 74.2M | 59.6M | 54.7M | 38.7M | 11.1M | 7.8M |
| Dividends Per Share | — | — | — | — | — | — | — |